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INTRODUCTION
Severe acute respiratory syndrome-coronavirus-2 (SARS-
CoV-2) infection can cause a wide array of symptoms rang-
ing from mild to severe or fatal forms of coronavirus dis-
ease 2019 (COVID-19).1 Furthermore, it has been observed
that in a proportion of patients a variable range of symp-
toms may persist for a long time.2
An increasing number of studies have been focused on
long COVID, but they have mainly been concentrated on
previously hospitalized severe COVID-19 patients report-
ing symptoms up to 6-months after illness.3,4 The main
aim of this study was to evaluate the prevalence of COVID-
related symptoms 12-months after the onset of mild-to-
moderate disease.
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METHODS
We conducted a prospective study on mild-to-moderate
symptomatic patients consecutively assessed between
March 1 and March 31, 2020, who tested positive for
SARS-CoV-2 RNA by polymerase chain reaction (PCR) on
nasopharyngeal and throat swabs performed according to
World Health Organization recommendation. An interdis-
ciplinary task force of medical doctors and nurses was
created in our region in response to the COVID-19 pan-
demic in order to monitor all isolated patients with PCR-
confirmed SARS-CoV-2 infection. The task force provided
us with the names and telephone contacts of the home-
isolated COVID-19 patients. The study was approved by
the Ethics Committee of the Friuli Venezia Giulia Region
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(CEUR-2020-Os-156). Additional informed consent was
obtained from all individual participants for whom iden-
tifying information is included in this article.
In order to have a homogeneous population of patients
who could be contacted by telephone, only mild-to-
moderately symptomatic subjects were included in the
study. Patients were considered mild-to-moderately symp-
tomatic if they had less severe clinical symptoms, oxy-
gen saturation (SpO2) ≥ 94%, not requiring hospitaliza-
tion, and therefore considered suitable for being treated
at home. Asymptomatic patients were not included in the
study.
Of the 496 eligible patients, 354 (71.4%) completed the
baseline telephone interview, whichwas conductedwithin
3 weeks after the first positive swab performed fromMarch
1, 2020 to March 31, 2020. The median time from onset of
symptoms to SARS-CoV-2 testing was 7 days (interquartile
range [IQR], 4–12 days). All patients completing the base-
line interview were phoned from March 5, 2021 to March
22, 2021, so that all patients were re-contacted 12-months
after the onset of symptoms; in case of a nonresponse,
patients were re-contacted twice.
Finally, of the 354 patients who completed the survey at
baseline, 304 completed the 12-months follow-up survey
(85.9%) as well; no differences emerged between respon-
ders and nonresponders in terms of baseline sociodemo-
graphic and clinical characteristics, including the number
and the severity of symptoms (data not shown).
Differences in prevalence were evaluated through
Fisher’s exact test and odds ratio (OR) for symptoms per-
sistence was calculated according to multivariable uncon-
ditional logistic regression model.
RESULTS
Baseline sociodemographic and clinical characteristics of
304 patients are reported in Table 1. The median age of the
study cohort was 47 years (range, 18–76 years).
During the acute phase of COVID-19 themost frequently
reported symptoms were fever (n = 232, 76.3%), felt tired
(n = 216, 71.1%), smell impairment (n = 201, 66.1%), taste
impairment (n= 198, 65.1%), and joint pain (n= 181, 59.5%)
(Figure 1).
Persistence of at least one symptom at 12 months was
reported by 161 patients (53.0%) with the most frequent
being "felt tired" (n= 83, 27.3%), followed by "smell or taste
impairment" (n = 67, 22.0%), "shortness of breath" (n = 39,
12.8%), and "muscle pain" (n = 28, 9.2%).
The risk of symptom’s persistence at 12-months follow-
up was trending upward in females (OR = 1.64; 95% con-
fidence interval [CI], 1.00–2.70; p = 0.051), and signifi-
cantly higher in subjects aged between 40 and 54 years
TABLE 1 Sociodemographic and clinical characteristics of 304
























Cardiovascular disease 26 (8.6)




Liver disease 5 (1.6)
Kidney disease 2 (0.7)
Time for a negative swab (days)
≤23 157 (51.6)
>23 147 (48.4)
Abbreviations: BMI, body mass index; COVID-19, coronavirus disease 2019;
IQR, interquartile range.
aMedian age (IQR): 47 years (37–56 years).
(OR = 1.92; 95% CI, 1.07–3.44; p = 0.029) and in those with
a body mass index BMI ≥ 25 k/mg2 (OR = 1.67; 95% CI,
1.00–2.78; p= 0.049). The presence of three to seven symp-
toms during the acute phase of the disease was associated
with a significantly higher chance of symptoms persistence
after 12 months (OR = 3.22; 95% CI, 1.01–10.24; p = 0.048),
with this association being stronger in those having
eight or more symptoms (OR = 8.71; 95% CI, 2.73–27.76;
p < 0.001).
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F IGURE 1 COVID-19-related symptoms. The percentages of patients with COVID-19-related symptoms during the acute phase of illness
(blue) and at 12-months follow-up (orange) according to severity (light, mild; dark, severe). Abbreviations: ARTIQ, Acute Respiratory Tract
Infection Questionnaire; COVID-19, coronavirus disease 2019.
DISCUSSION
Twelve months after the onset of illness, 53.0% of patients
with mild-to-moderate disease endorsed at least one per-
sistent symptom. A previous investigation in a large cohort
of previously hospitalized patients reported at least one
symptom in 76% of cases 6 months after acute infection,4
whereas in another study, including outpatients with mild
disease, ∼30% reported persistent symptoms at 6 months.5
Thus, taking into account that our series included only out-
patients with mild-to-moderate disease representing the
overwhelmingmajority of COVID-19 patients,6 the burden
of long haulers on the healthcare systems will be pressing
and urged researchers to identify strategies for prevention
and treatment and to plan education and rehabilitation ser-
vices in order to face with the considerable health and eco-
nomic concerns.2
In agreement with other evidence, the most commonly
reported symptom was fatigue followed by chemosensory
dysfunction.2 Chemosensory dysfunction has been consis-
tently reported as one of the most predominant symptom
during the acute phase of the disease as well as among
the most frequent long-lasting symptoms in patients with
COVID-19, with a higher prevalence in patients with
mild-to-moderate disease.7 Some authors have speculated
that mild-to-moderate COVID-19 patients may be affected
by nasal-centric viral spread, whereas patients requiring
hospitalization may be experiencing a more pulmonary-
centric and systemic viral infection, consequently impact-
ing the prevalence of different symptoms both in acute
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phase and in the context of long COVID syndrome.8 How-
ever, although all patients in the study were not formally
diagnosed with pneumonia having an SpO2 ≥ 94%, about
30% reported shortness of breath at the onset and 13% still
complained shortness of breath at 12-months follow-up
interview. Interestingly, an abnormal pulmonary function
consisting in an impaired diffusing-capacity was observed
in 30% of patients after the acute phase of mild COVID-19
without pneumonia.9 However, shortness of breath can be
a manifestation of underlying acute stress or anxiety with
these conditions being reported in patients with COVID-
19.4
Experiencing more symptoms at baseline was the most
significant factor associated with long COVID. Moreover,
the prevalence of long haulers was higher in females,
patients in their middle age, and those with BMI ≥ 25.
Thus, models to identify patients at risk for long COVID
may be developed.
This study has several limitations. First, the absence of
a control group may have an impact on the interpreta-
tion of results. Hospitalized patients were not included
in the study. Although this made our cohort more
homogeneous, studies comparing the long-term out-
comes in inpatients and outpatients are definitely needed.
Symptoms were self-reported and based on telephone
interview. Though we tried to perform a comprehensive
symptoms assessment, some symptoms may have been
undetected. Furthermore, a more precise evaluation of the
chemosensory function by psychophysical assessment was
lacking. Finally, a total of 14.1% of responders at base-
line did not complete the follow-up interview, thus intro-
ducing a potential bias in the results. Nonetheless, non-
responders were comparable to responders in terms of
symptoms frequency and severity, thus limiting selection
bias.
In conclusion, our study indicates that persistent symp-
toms of SARS-CoV-2 infection can be detected beyond 12
months from the onset of the illness in more than half
of outpatients. Identifying patients at risk for preven-
tion and treatment will be critical to improving outcomes
and reducing health costs. Finally, a structured and val-
idated questionnaire for the assessment of symptoms in
COVID-19 patients is highly desirable to characterize the
full clinical spectrum of long COVID and improve the reli-
ability and reproducibility of clinical studies.
CONFL ICT OF INTEREST
The authors declare that they have no conflicts of interest.
REFERENCES
1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC.
Pathophysiology, transmission, diagnosis, and treatment of Coro-
navirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782-
793.
2. Sudre CH,Murray B, Varsavsky T, et al. Attributes and predictors
of long COVID. Nat Med. 2021;27(4):626-631.
3. Carfì A, Bernabei R, Landi F. Gemelli against COVID-19 post-
acute care study group. Persistent symptoms in patients after
acute COVID-19. JAMA. 2020;324:603-605.
4. Huang C, Huang L, Wang Y, et al. 6-month consequences of
COVID-19 in patients discharged from hospital: a cohort study.
Lancet. 2021;397.
5. Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in
adults at 6 months after COVID-19 infection. JAMA Netw Open.
2021;4:e210830.
6. Gandhi RT, Lynch JB, del Rio C. Mild or moderate Covid-19. N
Engl J Med. 2020;383:1757-1766.
7. Boscolo-Rizzo P, Polesel J, Spinato G, et al. Predominance of
an altered sense of smell or taste among long-lasting symp-
toms in patients with mildly symptomatic COVID-19. Rhinology.
2020;58:524-525.
8. Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Asso-
ciation of chemosensory dysfunction and COVID-19 in patients
presenting with influenza-like symptoms. Int Forum Allergy Rhi-
nol. 2020;10(7):806-813.
9. Mo X, Jian W, Su Z, et al. Abnormal pulmonary function in
COVID-19 patients at time of hospital discharge. Eur Respir J.
2020;55(6):2001217.
How to cite this article: Boscolo-Rizzo P, Guida
F, Polesel J, et al. Sequelae in adults at 12 months
after mild-to-moderate coronavirus disease 2019
(COVID-19). Int Forum Allergy Rhinol. 2021;1-4.
https://doi.org/10.1002/alr.22832
